A new antibiotic showed promised results in a phase 3 clinical trial, providing hope for a disease on the brink of becoming untreatable. Due to the rise of antibiotic resistance, there is currently only one antibiotic capable of treating gonorrhea. Once the STI develops resistance to this last line of defense, physicians would not have any effective treatment options.
The new antibiotic, oral gepotidacin, proved to be safe and highly effective (93%) against the bacterial infection. If approved for use, it would be the first new class of antibiotics for gonorrhea in twenty years.
